Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women by Ambrosone, Christine B. et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2009, Article ID 871250, 15 pages
doi:10.1155/2009/871250
Clinical Study
ConductingMolecularEpidemiologicalResearch in the Age of
HIPAA: A Multi-Institutional Case-Control Study of Breast
Cancer in African-American and European-American Women
Christine B. Ambrosone,1 Gregory L. Ciupak,1 ElisaV.Bandera,2 Lina Jandorf,3
DanaH.Bovbjerg,4 GaryZirpoli,1 KarenPawlish,5 James Godbold,3 Helena Furberg,6
AnneFatone,3 HeiddisValdimarsdottir,3 SongYao,1 Yulin Li,1 Helena Hwang,1
Warren Davis,1 MichelleRoberts,1 LaraSucheston,1 Kitaw Demissie,7 Kandace L. Amend,8
Paul Tartter,9 James Reilly,10 BenjaminW.Pace,3 Thomas Rohan,11 Joseph Sparano,12
GeorgeRaptis,3 MariaCastaldi,13 Alison Estabrook,9 Sheldon Feldman,14 ChristinaWeltz,3
andMargaret Kemeny15
1Department of Cancer Prevention & Control, Roswell Park Cancer Institute, Elm & Carlton Streets, Buﬀalo, NY 14263, USA
2Cancer Institute of New Jersey, UMDNJ’s Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick,
NJ 08903-2681, USA
3Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA
4Department of Medicine, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
5Cancer Epidemiology Services, New Jersey State Department of Health and Senior Services, P. O. Box 369, Trenton,
NJ 08625-0369, USA
6Department of Genetics, University of North Carolina at Chapel Hill, 120 Mason Farm Road, 5000 D, GMB, CB number 7264,
UNC-Chapel Hill, Chapel Hill, NC 27599-7264, USA
7School of Public Health, University of Medicine and Dentistry of NJ, 683 Hoes Lane West, Building RWJ-SPH, Room 212,
Piscataway, NJ 08854, USA
8i3 Drug Safety, 5430 Data Court, Street number 200, Ann Arbor, MI 48108, USA
9Department of Breast and Oncology Surgery, St. Luke’s-Roosevelt Hospital, 1111 Amsterdam Avenue, New York, NY 10025, USA
10Department of Surgery, Kings County Hospital, Kings County Hospital Center, SUNY-Downstate College of Medicine,
451 Clarkson Avenue, Brooklyn, NY11203, USA
11Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Jack and Pearl Resnick Campus,
1300 Morris Park Avenue, Bronx, NY 10461, USA
12Departments of Medicine, Obstetrics and Gynecology, Monteﬁore Medical Center, Jack D. Weiler Hospital, 1825 Eastchester Road,
Room 2S-47-48, Bronx, NY 10461, USA
13Department of Surgery, Jacobi Medical Center, 1400 Pelham Parkway South, Bronx, NY 10461, USA
14Department of Surgery, New York-Presbyterian/Columbia, 161 Fort Washington Avenue, Street 1025, New York, NY 10032, USA
15Department of Surgical Oncology, Queens Cancer Center, Queens Hospital Center, 82-68 164th Street, New Bldg, 5th ﬂoor,
Jamaica, New York, NY 11432, USA
Correspondence should be addressed to Christine B. Ambrosone, christine.ambrosone@roswellpark.org
Received 28 April 2009; Revised 20 July 2009; Accepted 3 August 2009
Recommended by Dennis D. Weisenburger
Breast cancer in African-American (AA) women occurs at an earlier age than in European-American (EA) women and is more
likely to have aggressive features associated with poorer prognosis, such as high-grade and negative estrogen receptor (ER) status.
The mechanisms underlying these diﬀerences are unknown. To address this, we conducted a case-control study to evaluate risk
factors for high-grade ER- disease in both AA and EA women. With the onset of the Health Insurance Portability and Account-
ability Act of 1996, creative measures were needed to adapt case ascertainment and contact procedures to this new environment
of patient privacy. In this paper, we report on our approach to establishing a multicenter study of breast cancer in New York and
New Jersey, provide preliminary distributions of demographic and pathologic characteristics among case and control participants
by race, and contrast participation rates by approaches to case ascertainment, with discussion of strengths and weaknesses.2 Journal of Oncology
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Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
1.1. Rationale for the Study. Although breast cancer inci-
denceishigheroverallinwomenofEuropeandescentthanin
women of African ancestry, African-American (AA) women
are more likely than European-American (EA) women to
be diagnosed before age 40 and to have breast tumors with
more aggressive features, including high-grade and negative
estrogen receptor (ER) status (reviewed in [1]). There are no
facile explanations for these diﬀerences in the epidemiology
of breast cancer by ancestry. There have been several studies
of breast cancer risk that include both AA and EA women,
such as the Carolina Breast Cancer Study, the CARE Study,
and the Black Women’s Health Study; however, none were
speciﬁcally designed and powered to evaluate numerous risk
factors for early/aggressive breast cancer and to evaluate
the distribution of these risk factors within and across
racial/ethnic groups. Because of the large, racially mixed
population of women in metropolitan New York City (NYC)
and eastern New Jersey (NJ), we are currently conducting
a case-control study, the Women’s Circle of Health Study
(WCHS), with the goal of accruing 1200 AA and 1200 EA
women with breast cancer and an equal number of controls,
to speciﬁcally address these questions. Initial funding for this
study was through a Center of Excellence for Biobehavioral
Breast Cancer Research (Bovbjerg, PI) focusing on AA
women, funded by the Department of Defense (DOD).
Additional R01 funding (Ambrosone, PI) from the National
Cancer Institute (NCI) was subsequently obtained which
allowedustoincreasethesamplesizeandtoextendthestudy
to EA women. Additional facets of the study are funded by
the Breast Cancer Research Foundation.
2.MaterialsandMethods
As illustrated in Figure 1, the study has included two bases
for recruitment and interviewing, one in NYC, based at
Mount Sinai School of Medicine (MSSM), and one in NJ,
based at The Cancer Institute of New Jersey (CINJ), with
data and biospecimens sent to Roswell Park Cancer Institute
(RPCI) in Buﬀalo, NY, for processing and storage. In the
NYC metropolitan region, there are more than 60 hospitals
where surgery for breast cancer is performed. When this
study began in 2003, to maximize eﬃciency, we targeted
the hospitals that had the greatest referral patterns for AA
women in the boroughs of Manhattan, Brooklyn, Queens,
and the Bronx. Our initial plan was to employ the approach
commonly used in case-control studies, such as the Carolina
Breast Cancer Study [2] and the Long Island Breast Cancer
Study Project [3], wherein rapid case ascertainment is used
to identify women newly diagnosed with breast cancer
through periodic review of pathology reports in the targeted
hospitals. When women with breast cancer are identiﬁed, a
letter is sent to the treating physician, notifying them that
unless they object, the patient will be contacted to describe
the study and assess interest in participation.
We were unable to use this approach, however, due to
the implementation of the Health Insurance Portability and
Accountability Act (HIPAA) Privacy Rule in 2003, while
we were establishing the infrastructure for the study. This
extension of the HIPAA regulation prevents the release of
private health information (PHI) without consent from the
patient. For our research purposes, this Act prevented the
identiﬁcation of eligible cases without the patients’ prior
permission given to their doctors. Although there may
be situations in which an HIPAA waiver can be obtained
to circumvent the need to obtain patient permission for
release of identifying information to researchers [4, 5],
the several participating hospitals and their Institutional
Review Boards (IRB), many not extensively familiar with
epidemiological research, would not grant these waivers to
allow patient identiﬁcation. Thus, we developed a procedure
for patient ascertainment and contact that complied with the
regulations of HIPAA.
As an alternative strategy, we expanded our catchment
area to include eastern NJ, by partnering with CINJ and
the NJ State Cancer Registry, a Surveillance, Epidemiology
and End Results Program (SEER) site, housed at the NJ
State Department of Health and Senior Services (NJDHSS).
The study has been approved by the IRB at RPCI, Robert
Wood Johnson Medical School (for The CINJ), MSSM, the
individual hospitals in NYC, and the NJDHSS.
In this paper we report on both of our approaches
to case ascertainment and consenting, discussing eﬀort
and costs associated with each methodology. Currently,
recruitment eﬀorts are focused only in NJ, and accrual has
been discontinued in NY. We also present an overview of
the study design, report on distributions of demographic
and selected breast cancer risk factors among both cases and
controls by race/ethnicity, and compare clinical breast cancer
characteristics between groups in a subset of the population
enrolled to date.
2.1. Hospital-Based Case Ascertainment and Contact: New
York City. AA and EA women, 20 to 65 years of age, with
no previous history of cancer other than nonmelanoma skin
cancer, diagnosed within 9 months with primary, histolog-
ically conﬁrmed invasive breast cancer or ductal carcinoma
in situ who speak English were eligible for participation in
the study. They were ascertained from designated hospitals
that have large referral patterns for AA women in the
NYC boroughs (Manhattan, Bronx, Brooklyn, and Queens;
due to few AA breast cancer patients, Staten Island was
not included). To maintain comparability between cases
and controls, women with breast cancer must have had a
residential telephone given that controls were ascertainedJournal of Oncology 3
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Figure 1: Organization and administration of the Women’s Circle of Health Study.
using random digit dialing (RDD). This eligibility criterion
has now been expanded to cell phone usage, however, with
RDD also covering cell phones for control ascertainment.
ToaddressHIPAAregulationsthatprohibitidentiﬁcation
of women with breast cancer using pathology reports, tumor
registry data, or medical records, we worked to develop
collaborative relationships with physicians, research nurses,
and patient navigators at each of the participating hospitals.
Our research assistants initiated frequent visits to each site,
particularly on clinic days, and became well known by staﬀ
and clinic personnel. As we began working with physicians at
each site, clinicians reviewed their records for retrospective
ascertainment and identiﬁed women who were eligible to
be in the study (e.g., had been diagnosed within the last 9
months). At each of the participating hospitals, physicians
telephoned women who were not returning for followup and
would not be seen at subsequent visits, asking if WCHS staﬀ
could contact them regarding the study. Those scheduled for
routine followup appointments within the 9-month interval
were seen and asked if they were willing to be contacted
for this study. For contemporaneous recruitment, our study
staﬀ was present in the oﬃces on breast clinic days and was
informed by the physicians or research nurses at that time
of patients scheduled on those days who were eligible for
the study. Study materials were placed in the charts of the
eligible patients as a reminder for the clinician to discuss
the study. If in agreement, the patient was then referred to
our waiting study staﬀ. A number of patients participated
in the informed consent procedures at the time that they
were ﬁrst approached and a pretreatment blood specimen
was obtained. Other women preferred to be contacted at a
later date by the Research Assistant (RA)/Study Interviewer,
to schedule a date to obtain consent and conduct the in-
person interview.
Tostriveforcompletecaseascertainment,weperiodically
requested that physicians review their records to conﬁrm
that we had not missed potential cases, and that they follow
the procedures described above if there were women who
were not previously approached to participate in the study.
It was our intent that this periodic review would allow us to
estimate a denominator, to some extent, and to keep track
of women who refused to be contacted so that selection
bias could be examined. However, these data were not easily
obtained with our inability to access records of women
diagnosed who had not been approached, and competing
priorities of busy surgeons.
This approach to case ascertainment and contact yielded
good participation rates for both AA and EA cases but was
extremely labor intensive, requiring frequent communica-
tions between our research staﬀ and clinical personnel as
well as the presence of RAs at the hospitals on clinic days.
Besides being costly in personnel time, this methodology
required a good deal of dedication and commitment on the
part of physicians, with frequent reminders from study staﬀ
for them to check their appointment ledgers and contact
patientswhomayhavebeenmissedonclinicdays.Becauseof
all of the limitations of this approach, in 2006 we established
collaboration with the New Jersey State Cancer Registry,
based at the NJDHSS for rapid case ascertainment, and
phased out recruitment in metropolitan New York, ending
in December 2008.
2.2. Population-Based Case Ascertainment and Contact: New
Jersey. In NJ, cases are actively being identiﬁed at all major
hospitals in Passaic, Bergen, Hudson, Essex, Union, Middle-
sex, and Mercer Counties through rapid case ascertainment.
In addition, NJDHSS study staﬀ routinely check the New
Jersey State Cancer Registry (NJSCR) database for eligible
cases who reside in the target counties but are reported
by hospitals outside of those seven counties or out-of-
state. All AA women less than 65 years of age who are
newly diagnosed with incident breast cancer are identiﬁed
as potential participants. For each AA case, an EA woman
withbreastcancerisrandomlyselected,matchingonage(±5
years) and county of residence. NJDHSS study staﬀ review
pathology reports of potential cases, contact doctors’ oﬃces,
and hospitals to verify patients’ race and demographics and
checktheNJSCRdatabaseforpriordiagnosesofcancer.After4 Journal of Oncology
contact with clinicians by NJDHSS staﬀ for passive consent
(e.g., contact from physician only in the event that they do
notgivepermissiontocontacttheirpatients),eligiblewomen
are telephoned by NJDHSS staﬀ to obtain verbal consent to
release names and contact information to WCHS research
staﬀ at CINJ. Patients who agree to be contacted by WCHS
study staﬀ are then telephoned by one of our interviewers,
and appointments are scheduled for in-person interviews at
home or at another mutually convenient location.
2.3. Control Eligibility and Identiﬁcation: New York City and
New Jersey. AA and EA women 20 to 65 years of age without
a history of any cancer diagnosis other than non-melanoma
skin cancer are eligible to be controls. The choice of a
proper control group is a diﬃcult issue in epidemiology
today, particularly for a study that is not population-
based. When planning for the WCHS, we evaluated several
potential sources of control groups, weighing the strengths
and weaknesses for each. While we considered using hospital
controls in NYC, we felt that they would not necessarily
represent the same populations from which the cases were
derived. For example, many of the treating physicians at
MSSM have private surgical practices; there is no indication
that clinic patients from the hospital would be similar to
those being treated by private physicians. Furthermore, there
arewell-recognizedpotentialbiasesassociatedwiththeuseof
hospital controls [6]. In theory, the generalizability of study
results is likely to be greater in studies using community
controls rather than those using friend or hospital controls.
Yet, in contrast to the Western European national health care
records, none of the available United States (US) lists, such
as that of licensed drivers, municipal tax roles, voter regis-
tration, and listed phone numbers, provide complete source
population enumeration. Population coverage, access to this
information, and the quality of contact information vary
geographically in the US. Of NYC residents, it is estimated
that only 52.1% have drivers licenses [7], only 30.2% pay
residential taxes [8],andonly56.2% areregistered voters[9].
These examples typify the acknowledged weaknesses of US
and NYC sampling frames.
For generating a control group of adults under 65 years
of age we used random digit dialing (RDD) because unlisted
numbers can be reached by this method, thereby avoiding
possible selection bias (NYC study found that 27% of RDD
controls had unlisted numbers [10]). Thus, RDD provides
an ideal source when phone coverage is near complete; 93%
o fN Y Cr e s i d e n c e sh a v ep h o n e s[ 11]. High phone coverage
makesRDDoneofthebestsourcesforgeneratingasampling
frame for controls of NYC area women under 65 years of
age. Even when the source population is not solely deﬁned
by geography, a modiﬁed version of RDD is available that
creates a control sampling frame using the cases’ telephone
numbers [10, 12]. This is the approach that was used in
the WCHS in NY. RDD controls have been compared to
a privately conducted census population [13]a sw e l la st o
area survey controls [14], and both comparisons found that
RDD controls were similar to those from other sources.
Most importantly, high response rates within a minority
communityweredemonstratedusingthemodiﬁedWaksberg
RDD method [15], and in the WCHS, response rates among
minorities are similar to those among EA women. The
elimination of household landline phones in favor of cell
phones represents a challenge for telephone surveys based
on RDD to landline telephones [16, 17]. However, because
the percentage of households without landlines remains low
[17], any potential bias associated with this issue is likely to
be small. Furthermore, once subjects agree to participate in
the study, cell phones tend to facilitate scheduling interviews
and completing study materials because the calls go directly
to the participants and are not screened by other household
members.
For RDD in NYC, the telephone exchanges (area code
plus three-digit preﬁxes) of the breast cancer cases who
received medical care at the participating hospitals in
p r e v i o u sy e a r sw e r eu s e df o rs a m p l i n g .W ef r e q u e n c y
matched controls to cases on the expected breast cancer
case distribution (based on 1994–1998 data from the NYS
Tumor Registry) by 5-year age groups and race. The age
distribution of targeted controls was periodically modiﬁed
based upon the actual distributions of age among the cases.
Controls were identiﬁed, recruited, and interviewed in the
same manner and during the same time period as the cases
toeliminateanybiasrelatedtoseculartrendsorchangesover
the interviewing period.
In NJ, the same methodology is used for ascertainment
of eligible controls; however, rather than using telephone
numbers from participating hospitals, the entire county is
sampled, because cases include those from all hospitals in
the seven targeted counties. Controls, once identiﬁed, are
contacted to schedule an in-person interview; interviews are
conducted either at the participant’s home or at another
convenient location.
For both cases and controls in NYC and NJ who decline
participation, we request that they complete a short tele-
phone interview (5–10 minutes) to obtain basic information
on demographic and exposure factors. In the ﬁnal analysis,
data from women who refused study participation will be
compared to data from women who completed an interview
to evaluate potential bias related to non-participation.
Women who complete the study are oﬀered a $50 gift
certiﬁcate to one of several local stores as incentive for
participation. We had initially oﬀered $25 at the beginning
of the study, but later increased the amount due to inﬂation
and eﬀorts to increase participation.
2.4. Data Collection—Interviews and Specimen Collection.
The in-person interview consists of the informed consent
process, an in-depth in-person interview, completion of sev-
eral behavioral questionnaires including a Food Frequency
Questionnaire (FFQ), collection of biospecimens, and body
measurements. For cases, we also request a release for access
to medical records, pathology data and for tumor tissue, as
well as permission to conduct followup.
The survey instrument is an adaptation of several ques-
tionnaires, including validated surveys from the Women’s
Health Initiative and the Western New York Diet Study.
Developmental history questions were taken from the
Women’s Interview Study of Health (WISH) [18], andJournal of Oncology 5
lifetime physical activity is assessed using a modiﬁed version
of Friedenreich’s validated questionnaire [19]. Information
on medical history, family history of cancer, lifestyle factors
including smoking, alcohol consumption, and use of hair
products is also collected. The most recent version of the
FFQ developed at Fred Hutchinson Cancer Center and
validated in the NCI/SWOG Prostate Cancer Prevention
Trial is used for dietary assessment. This FFQ has been
validated for use in an AA population. At the end of the
visit, detailed measurements of current body size are taken.
Participants are asked to wear light clothing, as weight,
standing height, and waist, and hip circumferences are
measured.Bodycomposition(leanandfatmass)ismeasured
using a bioelectrical impedance analysis scale (Tanita scale).
Questionnaires are coded by two separate RAs, and double
data entry is performed by two separate clerks, with data
managed at RPCI.
Interviews take approximately 2 hours to complete,
including anthropometry measures. We initially collected
blood samples which were processed and stored in the
laboratory at MSSM. In 2007, to reduce costs and to facilitate
participation, we transitioned to collection of saliva using
Oragene Kits (DNA Genotek, Inc, Ottawa, ON, Canada) for
DNAextraction.Thesecollectionkitsyieldlargequantitiesof
high-quality DNA, comparable to that obtained from whole
blood [20, 21].
Periodically, DNA has been extracted in batches, using
the DNA Genotek Inc. protocol for DNA extraction from
saliva or the FlexiGene method (Qiagen Inc, Valencia, CA)
for whole blood or buﬀy coat. DNA is evaluated for purity
and concentration using a Nanodrop UV spectrophotometer
to obtain A230, A260, and A280 readings, and double
stranded DNA is quantitated using a PicoGreen-based ﬂuo-
rometric assay (Molecular Probes, Invitrogen Inc, Carlsbad,
CA). Saliva specimens have been stored at room temperature
until extraction, and DNA samples are stored at −80C at
RPCI.
2.5. Collection of Tumor Tissue Blocks and Clinical Data.
Formalin-ﬁxed paraﬃn-embedded blocks and correspond-
ing pathology reports from patients who signed the pathol-
ogy and tissue release have been retrieved from hospitals
on an ongoing basis. To date, 1193 patients have agreed
for release of their tumor tissue (91%), and this proportion
does not vary between NJ and NY. Pathology reports are
reviewed in order to identify a representative tumor block
used to make the primary breast cancer diagnosis for each
case. The tumor blocks are shipped to RPCI, where they are
labeled and entered into the tracking database. Hematoxylin
and eosin (H&E) slides are cut and reviewed by the study
pathologist (HH) to determine the locations from which
cores should be taken for construction of tissue microarrays
(TMAs), taking punches from both tumor and normal
tissues and for consistent determination of grade by one
pathologist. Representative tumor tissue is also labeled and
punches taken to be stored for future DNA extraction
and analysis. Pathology departments that do not release
blocks have instead been asked to process and cut the
requested number of slides (eleven unstained 5µ slides
and six unstained 10µ slides), which are then sent to the
laboratory at RPCI. Tissue blocks and pathology reports are
collected in tandem and include the abstraction of medical
record data. Because the consent process includes a tissue
block and medical record release form, and blocks are being
requested in “real time”, therehas been little resistanceon the
part of the hospitals to provide tissue.
2.6. Challenges and Adaptations to Meet Them. In estab-
lishing the infrastructure for this study, and making eﬀorts
to conduct a study based in community hospitals in the
face of stringent HIPAA and conﬁdentiality requirements,
our group brainstormed and adapted to achieve maximum
case ascertainment, contact of patients, and recruitment
into the study. With the help of committed and dedicated
clinicians,thisapproachwassuccessfulatsomehospitals,but
not all. Clearly, it places a burden on already busy clinical
practices, and it is likely that a complete denominator was
not available, due to patients overlooked or deemed not
suitable for participation in the study by their physician.
In our experience, this is not a practical way to conduct a
study and, unless one can ascertain cases through pathology
reports or medical records, the costs of such eﬀorts through
local hospitals may not justify the numbers of cases able to
be accrued. In contrast, by working through the NJDHSS,
an NCI SEER site, we capture all cases diagnosed within
a circumscribed area and truly know the denominator of
the study for calculation of response rates. An additional
advantage is that information on tumor characteristics is
available for non-participating cases.
The trade-oﬀ is in participation rates. In NYC, when
women were personally apprised of the study by their
physician,responserateswererelativelyhigh,with75%ofEA
and 75% of AA women completing interviews and providing
blood or saliva samples. However, we have no data on the
number of women who were eligible for the study and were
not approached by their physician, or those who requested
not to be contacted by our study staﬀ.
WhencontactedbytheNJDHSS,responseratesarelower
but still remain satisfactory. For EA women, 73% agreed to
be contacted by an interviewer, and 93% of those women
were interviewed and provided a saliva sample, for a total
participation rate of 68%. Participation was poorer for AA
women in NJ; 60% agreed to be contacted by an interviewer
when telephoned by staﬀ from the NJDHSS, and of those,
90% were enrolled into the study, for a total participation
rate of 54%. We have met approximately half of our accrual
goal, to date, and eﬀorts are constantly made to improve
response rates.
In NJ, the study is truly population-based. Newly
diagnosed patients from all hospitals in the 7 targeted
counties are ascertained and contacted by the NJDHSS.
These counties provide the population to be captured by
RDD as well. In NY, we focused on those hospitals with the
highest referral patterns for AAs in the 5 boroughs excluding
Staten Island, and it is clear that coverage was not complete.
While an average of 1273 cases per year are reported in
AA women in the boroughs, we were only able to ascertain
approximately67peryearthroughworkingwithcliniciansin6 Journal of Oncology
Table 1: Distribution of study participants by race, state, and case/control status as of June 2009. Numbers in tables vary, subject to status
of double data entry of questionnaires and receipt and entry of pathology reports.
Cases (n = 1,315) Controls (n = 1,097)
African American European American African American European American
New York City 339 342 356 336
New Jersey 284 350 93 312
Total 623 692 449 648
selectedhospitals. We expectthat thecontrolsampling frame
in NY results in a representative population, nonetheless,
because the ﬁrst three numbers of breast cancer patients seen
in previousyears ateach hospital wereused to obtain women
in the same residential areas.
When confronted with diﬃculties in case ascertainment
in NYC, we sought ways to expand eligibility criteria without
compromising the integrity of the study. We initially limited
eligibilityforcaseparticipantstothosebetweentheagesof20
to 64 years, primarily because of the low response rates using
RDD for controls 65 years and older. In 2007, we extended
the upper limit of age eligibility to 75 years for cases, but
not controls. Although these older women cannot be used
in case-control comparisons, they will allow for case-case
analysis of younger versus older age at onset of breast cancer,
in which age of the patient is the dependent variable. This
will allow us to explore possible diﬀerences in study variables
(e.g., aggressive versus non aggressive disease characteristics)
between older breast cancer patients and younger breast
cancer patients. We will also explore the possibility that such
diﬀerencesmightdiﬀerbyrace/ethnicitygroupsandbyother
disease characteristics deﬁned by pathology.
We had initially trained WCHS interviewers in phle-
botomy and made consent for specimen collection a require-
ment of the study. Three tubes of blood were collected and
processed, with straws stored with plasma, serum, red blood
cells (RBC), and buﬀy coat for DNA extraction. Our intent
was, when possible, to collect pretreatment blood samples to
be able to compare biomarkers in cases and controls and for
use later in studies of breast cancer prognosis. Because of the
diﬃculties in accrual in NYC, and in planning approaches in
NJ where we knew that we would not be able to coordinate
specimen collection prior to initiation of cancer therapy,
we decided to collect saliva as a source of DNA only, using
Oragene Saliva DNA Self-Collection Kits when we began
recruitment in NJ. Again, our ideal approach would be to
have pretreatment blood specimens on all cases, but in the
interests of cost and feasibility and what was viewed as long
term utility of samples other than DNA, compromises had to
be made. To date, we have serum, plasma, and RBCs banked
on 261 AA and 197 EA controls as well as 198 and 147 AA
and EA cases, respectively, which should provide us with
capabilities to investigate, in a limited sample set, diﬀerences
in biomarkers among controls only, and case control evalua-
tions for markers that are not likely to be aﬀected by surgery
or adjuvant therapy. All other cases and controls provided
saliva samples, and there are no participants in the study for
whom a source of DNA is not available.
3. Results
As noted above, case ascertainment and accrual in NYC
was terminated in 2008, and all eﬀorts are now ongoing
and focused on enrollment in NJ. Table 1 shows current
recruitment numbers for cases and controls, by race, in NYC
and in NJ. For the scope of this paper, we are reporting data
on the subset of cases and controls who have questionnaire
data which have been processed and veriﬁed through double
data entry, which includes 858 controls and 1119 cases. In
examining preliminary data through February 2009, there
are notable diﬀerences by race/ethnicity among participants.
Because we are still in data collection phase, we have made
limited comparisons between cases and controls in this
report. Rather, we have contrasted demographic and tumor
characteristics among AA and EA women in our study
samples. Among controls (Table 2), there are diﬀerences in
country of birth, with more AAs born in the Caribbean. EAs
are more likely to be married, to have graduated college,
and to have employer-provided health insurance. Higher
proportions of EA women have incomes above $90,000 per
year and EA women have fewer pregnancies and at a later
age than AAs. Rates of screening mammography are similar
between AA and EA women without breast cancer (86%
and 87%, resp.). Notably, AA controls are more likely to be
overweightthanEAs(30%versus25%)orobese(52%versus
26%) but are less likely to use hormone replacement therapy
(HRT) than EAs (15% versus 24%).
Demographic characteristics of cases (Table 3) and dif-
ferences by race/ancestry are, for the most part, similar to
distributions for controls in terms of birthplace, marital
status, education, health insurance, and income. Twenty
percent of AA women with breast cancer in our study either
do not have health insurance (17%) or pay for insurance out
of pocket (3%), compared to 12% of EA cases (4% with no
insurance, 8% self-purchased). In contrast to controls, where
useofmammographyissimilarbyrace/ancestry,only78%of
AA cases ever had a screening mammography, compared to
88% of EA women, and 51% of EA cases had their breast
cancer discovered by mammography versus only 36% of
AA women. There also appear to be greater diﬀerences by
race/ancestry for hormonal and reproductive factors among
cases than among controls. Twenty-nine percent of AA cases
experienced menarche at or below age 12, compared to only
24% of EA women; these diﬀerences are not as notable
among controls (27% versus 25%). African American cases
also tend to have more children and at an earlier age than
EA cases, similar to patterns observed among controls. AsJournal of Oncology 7
Table 2: Characteristics of 858 controls.
African American European American
N (412) % N (446) %
Age at interview
<35 21 5.1 22 4.9
35–39 21 5.1 37 8.3
40–49 119 28.9 127 28.5
50–59 172 41.8 194 43.5
60–64 73 17.7 61 13.7
65+ 6 1.5 5 1.1
Country of origin1
United States and Canada 280 68.0 390 87.4
Caribbean countries 63 15.3 0 0
Other 69 16.7 56 12.6
Marital status1
Married 143 34.9 277 62.1
Living as married 15 3.7 19 4.3
Widowed 21 5.1 17 3.8
Separated 34 8.3 15 3.4
Divorced 70 17.1 48 10.8
Single, never married or never lived as married 127 31.0 70 15.7
Highest grade of school completed1
Less than 11th grade 52 12.6 7 1.6
High school graduate or equivalent 91 22.1 30 6.7
Some college 128 31.1 87 19.5
College graduate 86 20.9 156 35.0
Post-graduate degree 55 13.4 166 37.2
Health insurance (multiple choices possible)
Medicaid1 70 17.0 17 3.8
Medicare1 17 4.1 7 1.6
Employer-provided insurance1 272 66.2 350 78.5
Pay for insurance out of pocket1 18 4.4 49 11.0
I do not have health insurance 29 7.0 23 5.2
Other 13 3.2 21 4.7
Annual income1
Less than $15000 51 13.4 15 3.6
$15000–19999 30 7.9 9 2.2
$20000–24999 25 6.5 5 1.2
$25000–34999 48 12.6 19 4.6
$35000–49999 68 17.8 42 10.2
$50000–69999 60 15.7 53 12.9
$70000–89999 45 11.8 61 14.8
$90000 or more 55 14.4 208 50.5
BMI1
Underweight 3 0.8 14 3.5
Normal 68 17.7 188 46.3
Overweight 115 30.0 100 24.6
Obese 198 51.6 104 25.68 Journal of Oncology
Table 2: Continued.
African American European American
N (412) % N (446) %
Age at menarche
<11 40 9.7 39 8.8
11-12 71 17.3 69 15.6
12-13 90 21.9 112 25.3
13-14 99 24.1 124 28.0
14+ 111 27.0 99 22.4
Number of pregnancies1
No pregnancies 36 9.9 91 23.4
1 pregnancy 89 24.4 90 23.1
2 pregnancies 103 28.2 126 32.4
3 pregnancies 74 20.3 56 14.4
4 pregnancies 31 8.5 8 2.1
5 + pregnancies 32 8.8 18 4.6
A g ea tﬁ r s tp r e g n a n c y 1
≤19 115 35.5 18 6.1
20–24 107 33.0 65 22.0
25–29 50 15.4 80 27.0
30+ 52 16.1 133 44.9
Age at menopause1
Premenopausal 114 32.4 158 38.7
Perimenopausal 104 29.6 117 28.7
≤44 26 7.4 13 3.2
45–49 44 12.5 31 7.6
50+ 64 18.2 89 21.8
Ever have hormone replacement therapy?1
Yes 63 15.4 105 23.6
No 347 84.6 340 76.4
Ever have a screening mammogram?
Yes 353 86.1 388 87.0
No 57 13.9 58 13.0
1P < .05, Chi-square or Fisher’s exact test, as appropriate, for diﬀerences between AAs and EAs.
observed for controls, AA women with breast cancer are also
more likely to be overweight (31%) or obese (53%) than EA
cases (26% and 26%, resp.) and are less likely to use HRT
than EAs (15% versus 27%).
Of the pathology reports abstracted to date, the char-
acteristics of tumors of women in our study are similar to
those noted in literature [1]. African-American women are
more likely than EA to have high-grade tumors (52% versus
32%) with ER negative (34% versus 22%) and PR negative
(48% versus 34%) status. There are negligible diﬀerences by
ancestry for HER2 status in our study population.
It is possible that diﬀering methods of ascertainment and
accrual could result in selection bias. We compared clinical
and some epidemiological data between participants in NY
and those in NJ. As shown in Table 4,A Ac a s e sf r o mN Y
are more likely to have less than 11th grade education (22%
versus 9%), more likely not to have health insurance (23%
versus 9%), or be receiving Medicaid (21% versus 8%).
Cases in NY had a lower incidence of DCIS (21% versus
13%),withinvasivecancersbeingslightlyhigher(87%versus
79%). These diﬀerences may be due to the fact that, in New
York, the majority of AA cases were ascertained at Kings
County Hospital in Brooklyn which serves a large Caribbean
community,manywithlowsocioeconomicstatus,orbecause
participation rates were higher in NY, resulting in some
selection bias among those who agreed to be contacted in NJ.
For EA patients (Table 5), NY cases were more likely to
be postgraduates (36% versus 22%) and but were less likely
to have insurance (5% versus 2%) and receive Medicaid (4%
versus 0%). Cases in NY were less likely to be obese (32%
versus 22%) and had an older age at menarche (52% versus
42%).Journal of Oncology 9
Table 3: Characteristics of 1119 breast cancer cases.
African American European American
N (559) % N (560) %
Age at interview
<35 28 5.0 17 3.0
35–39 33 5.9 32 5.7
40–49 179 32.0 179 32.0
50–59 207 37.0 198 35.4
60–64 79 14.1 89 15.9
65+ 33 5.9 44 7.9
Country of origin1
United States and Canada 338 60.5 472 84.3
Caribbean countries 130 23.2 8 1.4
Other 91 16.3 80 14.3
Marital status1
Married 195 35.1 354 63.5
Living as married 13 2.3 17 3.1
Widowed 37 6.7 23 4.1
Separated 49 8.8 10 1.8
Divorced 93 16.7 61 11.0
Single, never married or never lived as married 169 30.4 92 16.5
Highest grade of school completed1
Less than 11th grade 94 16.8 13 2.3
High school graduate or equivalent 155 27.7 81 14.5
Some college 160 28.6 120 21.5
College graduate 98 17.5 180 32.2
Post-graduate degree 52 9.3 165 29.5
Health insurance (multiple choices possible)
Medicaid1 87 15.6 13 2.3
Medicare 39 7.0 31 5.6
Employer-provided insurance1 328 58.7 455 81.4
Pay for insurance out of pocket1 18 3.2 42 7.5
I do not have health insurance1 95 17.0 22 3.9
Other 19 3.4 20 3.6
Annual income1
Less than $15000 103 20.9 25 4.9
$15000–19999 66 13.4 11 2.2
$20000–24999 37 7.5 12 2.4
$25000–34999 54 10.9 14 2.8
$35000–49999 66 13.4 50 9.9
$50000–69999 67 13.6 54 10.7
$70000–89999 39 7.9 68 13.4
$90000 or more 62 12.6 273 53.9
BMI1
Underweight 6 1.2 9 1.8
Normal 78 15.5 239 46.4
Overweight 156 30.9 132 25.6
Obese 265 52.5 135 26.210 Journal of Oncology
Table 3: Continued.
African American European American
N (559) % N (560) %
Age at menarche1
<11 72 12.9 48 8.7
11-12 87 15.6 83 15.0
12-13 120 21.5 160 28.9
13-14 132 23.7 146 26.3
14+ 147 26.3 117 21.1
Number of pregnancies1
No pregnancies 43 8.4 117 23.9
1 pregnancy 112 21.8 101 20.7
2 pregnancies 161 31.4 166 33.9
3 pregnancies 94 18.3 68 13.9
4 pregnancies 51 9.9 24 4.9
5 + pregnancies 52 10.1 13 2.7
A g ea tﬁ r s tp r e g n a n c y 1
≤19 172 37.1 27 7.3
20–24 140 30.2 93 25.0
25–29 88 19.0 110 29.6
30+ 64 13.8 142 38.2
Age at menopause1
Premenopausal 200 43.4 207 40.8
Perimenopausal 115 24.9 97 19.1
≤44 28 6.1 20 3.9
45–49 46 10.0 54 10.6
50+ 72 15.6 130 25.6
Ever have hormone replacement therapy?1
Yes 82 14.8 152 27.2
No 473 85.2 406 72.8
Ever have a screening mammogram?1
Yes 435 78.0 492 88.2
No 123 22.0 66 11.8
How was your breast cancer found?1
Routine self-exam 144 26.0 63 11.4
Accidental self discovery 128 23.2 106 19.1
Accidental discovery by a partner 6 1.1 4 0.7
Routine physical exam by a doctor 37 6.7 42 7.6
Routine mammogram 198 35.8 283 51.0
Some other way 40 7.2 57 10.3
ER status1
Positive 231 65.6 203 77.8
Negative 121 34.4 58 22.2
PR status1
Positive 181 51.7 172 66.4
Negative 169 48.3 87 33.6
HER2
Positive 83 27.7 41 20.8
Negative 217 72.3 156 79.2
Grade1
Well-diﬀerentiated 35 8.6 68 20.9
Moderately diﬀerentiated 162 39.8 153 47.1
Poorly diﬀerentiated 210 51.6 104 32.0
1 P < .05, Chi-square or Fisher’s exact test, as appropriate, for diﬀerences between AAs and EAs.Journal of Oncology 11
Table 4: Characteristics of 559 African American breast cancer cases.
New Jersey New York
N (226) % N (333) %
Age at interview
<40 20 8.9 41 12.3
50–59 154 68.1 232 69.7
60+ 52 23.0 60 18.0
Highest grade of school completed1
Less than 11th grade 20 8.9 74 22.2
High school graduate or equivalent 63 27.9 92 27.6
Some college 76 33.6 84 25.2
College graduate 43 19.0 55 16.5
Postgraduate degree 24 10.6 28 8.4
Health insurance (multiple choices possible)
Medicaid1 18 8.0 69 20.7
Medicare 16 7.1 23 6.9
Employer-provided insurance1 169 74.8 159 47.8
Pay for insurance out of pocket 10 4.4 8 2.4
I do not have health insurance1 20 8.9 75 22.5
Other 10 4.4 9 2.7
BMI
Underweight 1 0.5 5 1.6
Normal 28 14.1 50 16.3
Overweight 59 29.8 97 31.6
Obese 110 55.6 155 50.5
First degree relative with breast cancer
Yes 37 16.4 45 13.5
No 189 83.6 288 86.5
Age at menarche
<11 27 12.0 45 13.5
11–13 82 36.4 125 37.5
13+ 116 51.6 163 49.0
ER status
Positive 45 68.3 76 63.8
Negative 97 31.7 134 36.2
Grade
Well-diﬀerentiated 15 8.2 20 8.9
Moderately diﬀerentiated 72 39.3 90 40.0
Poorly diﬀerentiated 96 52.5 115 51.1
Histologic type1
DCIS 43 20.8 30 13.0
Invasive 164 79.2 201 87.0
1 P < .05, Chi-square or Fisher’s exact test, as appropriate, for diﬀerences between states.
Diﬀerences between controls in NY and NJ (Tables 6 and
7) showed some similar patterns as those for cases. NY AA
controls were more likely to be on Medicaid (18% versus
10%) and were more likely to be obese (55% versus 34%).
Similar diﬀerences were noted for EA controls.
It is diﬃcult to ascertain the representativeness of our
participants in relation to the underlying populations they
were derived from. However, we did ask those who refused
to be interviewed to complete a short telephone interview. In
NY, cases who refused tended to be older >49, insured, either12 Journal of Oncology
Table 5: Characteristics of 560 European American breast cancer cases.
New Jersey New York
N (252) % N (308) %
Age at interview
<40 18 7.1 31 10.1
50–59 166 65.9 211 68.7
60+ 68 27.0 65 21.2
Highest grade of school completed1
L e s s t h a n 1 1 t h g r a d e 62 . 472 . 3
High school graduate or equivalent 47 18.7 34 11.1
Some college 60 23.8 60 19.5
College graduate 83 32.9 97 31.6
Postgraduate degree 56 22.2 109 35.5
Health insurance (multiple choices possible)
Medicaid1 0 0.0 13 4.2
Medicare 15 6.0 16 5.2
Employer-provided insurance1 220 87.7 235 76.3
Pay for insurance out of pocket 17 6.8 25 8.1
I do not have health insurance 6 2.4 16 5.2
Other 9 3.6 11 3.6
BMI1
Underweight 2 0.9 7 2.5
Normal 98 42.6 141 49.5
Overweight 57 24.8 75 26.3
Obese 73 31.7 62 21.8
First degree relative with breast cancer
Yes 58 23.0 83 27.0
No 194 77.0 225 73.0
Age at menarche1
<11 25 10.0 23 7.5
11–13 120 48.2 123 40.3
13+ 104 41.8 159 52.1
ER status1
Positive 109 77.9 28 77.4
Negative 31 22.1 96 22.6
Grade
Well-diﬀerentiated 43 22.8 25 18.1
Moderately diﬀerentiated 88 46.6 65 47.1
Poorly diﬀerentiated 58 30.7 48 34.8
Histologic type
DCIS 56 25.2 40 27.6
Invasive 166 74.8 105 72.4
1 P < .05, Chi-square or Fisher’s exact test, as appropriate, for diﬀerences between states.
through Medicaid, Medicare, or employee-based insurance,
have never taken hormone replacement therapy, and have
had screening mammograms. Similar diﬀerences were noted
for cases in NJ and for controls (insured, no HRT, and higher
prevalence of screening mammograms). For controls, those
who refused were more likely to have employer-provided
insurance. The higher participation rates of cases in NY
suggest that there would be less selection bias than in NJ,
particularlyforAAcases,becauseoflowerparticipationrates
in NJ. On the other hand, the population of cases in NYJournal of Oncology 13
Table 6: Characteristics of 412 African American controls.
New Jersey New York
N (63) % N (349) %
Age at interview
<40 11 17.5 30 8.6
40–59 40 63.5 252 72.2
60+ 12 19.0 67 19.2
Highest grade of school completed1
Less than 11th grade 7 11.1 45 12.9
High school graduate or equivalent 13 20.6 77 22.1
Some college 18 28.6 110 31.5
College graduate 15 23.8 71 20.3
Postgraduate degree 10 15.9 46 13.2
Health insurance (multiple choices possible)
Medicaid 6 9.5 63 18.1
M e d i c a r e 34 . 81 44 . 0
Employer-provided insurance 43 69.4 230 65.9
Pay for insurance out of pocket 3 4.8 15 4.3
I do not have health insurance1 4 6.4 25 7.2
Other1 5 7 . 982 . 3
BMI1
U n d e r w e i g h t 0 0 . 020 . 6
Normal 15 26.8 54 16.5
Overweight 22 39.3 93 28.4
Obese 19 33.9 179 54.6
First degree relative with breast cancer
Y e s 57 . 93 49 . 7
No 58 92.1 315 90.3
Age at menarche
<11 6 9.5 35 10.1
11–13 26 41.3 135 38.8
13+ 31 49.2 178 51.2
1 P < .05, Chi-square or Fisher’s exact test, as appropriate, for diﬀerences between states.
is somewhat skewed towards those treated at the County
Hospital, where there is a large Caribbean population.
4. DiscussionandFutureDirections
When embarking on the conduct of a case-control study,
an u m b e ro ff a c t o r ss h o u l db ec o n s i d e r e dw i t hr e s p e c tt o
methodology. Uppermost in importance is feasibility, which
is often overlooked by young, eager investigators. Although
we recruited and interviewed over 500 cases through hospi-
tals in NYC, the approach was often a struggle, and there is
no question that case ascertainment through collaboration
with a state SEER Cancer Registry is much more eﬃcient.
Using this approach, we are currently interviewing over
60 women per month, with numbers expected to rise
with additional interviewers hired. We are conﬁdent that
we will reach our accrual goals within the next 24 to 36
months, with ample power to evaluate our main study
hypotheses, yielding important information regarding the
etiology of aggressive breast cancers among AA as well as
EA women. Since initiating the study, scientiﬁc knowledge
has advanced, and while our earlier aims were to categorize
women according to age at onset, tumor grade, and ER
status, we are currently reclassifying tumor grade based on
readings from one pathologist and building TMAs with
fundingfromtheBreastCancerResearchFoundationtostain
and read all tissue for ER, PR, and HER2 for assessment of
triple negative breast cancers as well as cytokeratins 5 and
6 and HER1 to help classify basal-like breast cancers. The
successful enrollment of cases and controls, and collection
of tissue blocks, has also facilitated numerous collaborations
for pooled studies to conduct genomewide association
studies and to determine the extent of African admixture
in relation to tumor characteristics. With tumor tissue DNA14 Journal of Oncology
Table 7: Characteristics of 446 European American controls.
New Jersey New York
N (124) % N (322) %
Age at interview1
<40 23 18.6 36 11.2
40–59 89 71.8 232 72.1
60+ 12 9.7 54 16.8
Highest grade of school completed
L e s s t h a n 1 1 t h g r a d e 10 . 861 . 9
High school graduate or equivalent 8 6.5 21 6.5
Some college 31 25.2 56 17.4
College graduate 44 35.8 112 34.8
Post-graduate degree 39 31.7 127 39.4
Health insurance (multiple choices possible)
Medicaid 2 1.6 15 4.7
Medicare 1 0.8 6 1.9
Employer-provided insurance1 105 85.4 244 75.8
Pay for insurance out of pocket 12 9.7 37 11.5
I do not have health insurance 6 4.8 17 5.3
Other 3 2.4 18 5.6
BMI
Underweight 1 0.8 13 4.5
Normal 48 41.0 140 48.6
Overweight 34 29.1 65 22.6
Obese 34 29.1 70 24.3
First degree relative with breast cancer
Yes 15 12.1 49 15.2
No 109 87.9 273 84.8
Age at menarche
<11 14 11.5 25 7.8
11–13 50 41.0 131 40.9
13+ 58 47.5 164 51.3
1 P < .05, Chi-square or Fisher’s exact test, as appropriate, for diﬀerences between states.
as well as TMAs in addition to the epidemiologic data and
biospecimens, we will have numerous opportunities not
only to address our primary hypotheses but also to address
novel hypotheses regarding ethnic/racial disparities in breast
cancer incidence and mortality.
5. Conclusion
Epidemiological research has become increasingly diﬃcult
withthegrowingconcernsregarding privacyandlegalissues.
Tobeabletoaddresspressingissuesinbreastcancerresearch,
particularly causal factors for the more aggressive breast
cancers in AA women, creative strategies are required to
conduct hospital and population-based studies. Partnership
with SEER site is one approach for successful and complete
case ascertainment and can facilitate the needed research in
breast cancer disparities.
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